Shares of McKesson fell 1.2% following its Q3 2025 earnings release on Feb. 5 due to a weaker-than-expected adjusted EPS of $8.03 and revenue of $95.3 billion. The Medical-Surgical Solutions ...

Despite weaker-than-expected Q3 2025 adjusted EPS of $8.03 and revenue of $95.3 billion, McKesson shares rose marginally on Feb. 5. The U.S. Pharmaceutical segment's 19% revenue growth ...

Q3 2027 earnings at $11.90 EPS and FY2027 earnings at $41.06 EPS. Get McKesson alerts: McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th.

Valued at a market cap of $80.4 billion, McKesson Corporation (MCK) is a leading healthcare services and information ...

McKesson (MCK) came out with quarterly earnings of $8.03 per share, missing the Zacks Consensus Estimate of $8.04 per share. This compares to earnings of $7.74 per share a year ago. These figures ...

Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, ...

McKesson delivered robust Q3 earnings, reflecting its strong position in the healthcare distribution sector. While specific figures were not detailed, the company's performance suggests resilience ...

But there’s a powerful fundamental story happening with McKesson. Also, EPS is estimated to ramp higher this year by +12.4%. Now it makes sense why the stock has been powering to new heights.

The pharmaceutical firm’s consolidated revenue from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in earnings.

Q3 Results, Earnings Today: Companies like Parle Industries, Easy Trip Planners, Bajaj Consumer Care, ABFRL, Ethos and many others are releasing their Q3 results today. (Image Source: Freepik ...